NEW YORK (GenomeWeb) – Bristol-Myers Squibb and Denmark's Nordic Bioscience have announced a collaboration to develop biomarkers to help diagnose and monitor scar-tissue related to diseases of the liver.

Under the terms of the agreement, the partners will develop biomarkers and diagnostics to evaluate non-alcoholic steatohepatitis (NASH) in pre-clinical models of fibrotic diseases and in clinical settings.

Nordic Bioscience brings to the collaboration experience developing assays using collagens, elastins, and laminins as biomarkers of the extracellular matrix.